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Abstract:  There is a need for a blood biomarker of disease activity in ALS. This marker needs 
to measure the loss of motor neurones. Phosphorylated neurofilament heavy chain (pNfH) in the 
serum is a biomarker of axonal injury. Previous studies have found that levels of pNfH are 
elevated in ALS. We have performed a serial study of pNfH levels in 98 subjects from our ALS 
clinic. There was significant elevation of levels of pNfH in subjects with ALS compared to 
controls, although there was considerable variability. In studies of individuals who had two or 
more serial samples, we found that the levels of pNfH increased over time in the early stage of 
disease. Levels were low in subjects with long survival. The rate of rise of pNfH was inversely 
correlated with survival. We suggest that the initial level of pNfH is a marker of disease severity 
and that changes in pNfH levels are markers of disease progression.  
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1.  Introduction 
There is a need for a biomarker of disease progression in amyotrophic lateral sclerosis (ALS), to 
assist with prognosis and for use in clinical trials [1;2] with a blood biomarker being most 
convenient [3]. Neurofilament (Nf) heavy protein (NfH) is one of the three neuronal cytoskeleton 
intermediate filament subunit proteins; the others being neurofilament medium protein and light 
protein  [4].  Phosphorylated NfH (pNfH) is a major constituent of axons and release of pNfH 
protein is considered to be a biomarker of axonal injury [5]. In cerebrospinal fluid (CSF), 
accumulation of pNfH has been demonstrated in animal models of spinal cord injury and brain 
injury [5;6]. In the blood, elevated levels of pNfH have been demonstrated in animals with focal 
brain injury [7] and focal brain ischaemia  [8]. In human subjects, elevated levels of pNfH have 
been found in the serum of subjects with acute ischaemic stroke [9;10] and subjects with acute 
brain injury after cardiac arrest [11]. Since the pathology of ALS is death of motor neurones and 
loss of their axons, pNfH is a possible biomarker of disease progression in ALS. 
Studies to date have found elevation of pNfH in CSF in animal models [5;6] and in humans with 
ALS [12;13]. Elevated levels of pNfH have also been demonstrated in the blood of subjects with 
ALS [14;15].  There is one study showing that CSF and plasma levels of pNfH are correlated 
[16]. Histological studies have demonstrated the loss of NfH and pNfH from brain and spinal 
cord tissue in ALS subjects [17], and that there is aggregation of Nf within cells as disease 
progresses [18].  Levels of pNfH have been linked to disease severity, with the rate of change of 
ALS functional rating scale (ALSFRS) being greater in subjects with higher levels of pNfH in 
the blood [18] and high levels early in disease being linked with more rapid progression [15]. We 
have performed a study of subjects from our ALS clinic, to measure pNfH levels over time and 
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to correlate these with survival. Even in subjects who fulfil the diagnostic criteria for clinically 
definite disease [19], ALS is heterogenous [20].  The variable features of ALS include length of 
survival, with a subgroup of patients with ALS showing survival greater than 5 years [21],  site 
of onset and relative severity of upper and lower motor neurone signs [20;22-24].  These features 
could be associated with different rate of progression of disease, so  we have also studied levels 
of pNfH in subjects with different clinical features.  
2.  Materials and Methods 
2.1 Subjects and Blood Collection 
For this study we used samples from 98 consecutive subjects from our ALS clinic who consented 
to the study. Subjects with typical ALS fulfilled the criteria for diagnosis of ALS at the time of 
blood collection, and had mixed upper and lower motor neurone signs [19]. We also included 
patients from the clinic who had both upper and lower motor neurone signs, and fulfilled the 
diagnostic criteria, but had predominant upper motor neurone (UMN) weakness, as previously 
described [22;25] or predominant lower motor neurone  (LMN) weakness, as described [25;26].  
At the end of the study, 65 patients were deceased. Survival was calculated from the onset of 
disease until death or the end of the study. Blood was collected every 3 months when possible. 
Blood was collected on up to 9 occasions with a total of 223 ALS samples. We also collected 
blood from 61 healthy controls. The details of the subjects are shown in Table 1. The subjects 
with typical ALS, and UMN and LMN predominant disease are shown in Table 2. The site of 
onset (bulbar, upper limb or lower limb) was noted and the numbers in these groups are also 
shown in Table 2. Subjects were evaluated with the ALS functional rating scale-revised 
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(ALSFRS-R) [27]. This was was not done systematically, but the ALSFRS-R score was recorded 
at the time of blood collection on at least one occasion on 50 subjects and on multiple occasions 
on 24 of those subjects. For the subjects with multiple recorded values, we calculated the rate of 
change of ALSFRS-R. Our study included subjects with typical ALS with short survival and also 
included subjects with clincally definite ALS who had prolonged survival. To study these two 
groups separately, we used an arbitrary cutoff, and classed subjects into those with survival of 
<1500 days and those with >1500 days.  
2.2 Blood Collection  
Venous blood (6 ml) was taken into a serum tube (BD Vacutainer Plus Red Serum Tube, Cat# 
367837) and the tube was left in a standing position at room temperature for 30 min to allow 
blood clotting. The sample was then centrifuged at 1500 rpm for 10 min at room temperature. 
The serum was separated and aliquots were stored at -80
o
C.   
2.3  pNfH ELISA  
The serum concentrations of pNfH were detected with a pre-coated pNfH enzyme linked 
immune-sorbent assay (ELISA) kit, using polyclonal antibody to NfH (EnCor Biotechnology 
Inc., Gainesville, FL, USA) [5]. We used undiluted serum. The assay was performed according  
to the manufacturer’s instructions. In brief, 50 μL of undiluted serum from patients and controls 
was added in triplicate. A standard curve was prepared for each plate using 12 serial doubling 
dilutions of purified bovine pNfH protein (provided by the kit), ranging from 0 –12.5 ng/ml.  The 
reaction was developed using 100 µL of Trimethylbenzidine (TMB)-peroxidase, and 
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subsequently stopped using 50 µL of 2N sulphuric acid. Between the loading of the serum and 
the addition of the detection antibody and also between the addition of the detection antibody 
and the addition of TMB-peroxidase, the ELISA plate was incubated for one hour at room 
temperature.  Plates were washed 10x between incubation steps using the recommended wash 
buffer. Absorbance values were determined by reading the plates at 450 nm using a Paradigm 
Plate Reader (Beckman Coulter, Gladesville, Sydney, Australia). Serum pNfH levels for all 
groups were calculated from the standard curve.  
We selected samples from one subject with a high values and one with a low value of pNfH and 
studied these samples  in multiple ELISA plates. The co-efficients of variation were  0.33 and 
0.38, respectively. We did not make a systematic study of the possibility of a "hook effect", 
whereby the concentration of protein measured by the assay is greater when samples are diluted 
[28;29]. However, we studied two samples undiluted, and in 1:2 and 1;4 dilutions. For these 
samples, there was an increase in the concentration of pNfH after dilution, suggestive of a "hook 
effect".  
 
2.4  Calculation of Rate of Rise of pNfH and Rate of Change of ALSFRS-R 
We calculated the rate of rise of pNfH, by using the slope of the linear regression curve for all 
available values. We calculated the rate of change of ALSFRS-R by using the slope of the linear 
regression curve for all available values.  
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2.5  Statistical Methods and Graphs  
Statistical analysis, curve fitting and graphs were done with GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego California USA).  Groups were compared using 
Kruskal Wallis one-way ANOVA corrected for multiple comparisons, and Mann Whitney test 
for comparing two groups.  The rate of change of pNfH and of the ALSFRS-R was the slope of 
the linear regression curve. Linear regression analysis was used to correlate pNfH levels and rate 
of rise of pNfH with survival and ALSFRS-R and rate of change of ALSFRS-R.  
3. Results  
3.1 Serum Levels of pNfH are Elevated in Subjects with ALS 
Figure 1 shows the levels of pNfH in all samples combined, for the first sample and for the peak 
samples, which were the highest recorded level for subjects with multiple samples, and the first 
value for subjects with only one sample. The levels were significantly greater in subjects with 
ALS than in healthy controls. A value greater than 1.5 ng/ml was only seen in ALS subjects. As 
with clinical trials of ALS, our study included subjects with long survival. When the subjects are 
subdivided into those who survived until death or censoring for less than 1500 days, and those 
with survival greater than 1500 days, it can be seen that those with a shorter survival time have 
higher pNfH levels and peak pNfH levels. This suggests that higher levels are found in more 
severe and rapidly progressing disease with shorter survival. 
 3.2   pNfH Levels Change Over Time 
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For those subjects with serial samples, the results are shown in Figure 2A. In 33 of 55 subjects 
(60%) there was a rise of pNfH levels from the first to the second sample, and in 21 of 34 
subjects (62%) there was a rise from the first to the third sample.  For all samples that were 
collected, Figure 2B and Figure 2C show the average trajectories of pNfH levels for subjects 
with survival less than 1500 days, and those with survival greater than 1500 days, respectively, 
fitting a second order polynomial curve. These  show that, on average, there was a rise and then a 
fall in pNfH levels, but there is considerable variability among subjects.  
Figure 3A shows the values for the first, second, third and fourth and later samples. The levels at 
each collection were greater than for controls. The levels of pNfH were greater in the later 
samples.  For all samples that were collected, as shown in Figures 3B and 3C, when subjectswere 
subdivided into those with survival less than or greater than 1500 days, and the samples stratified 
according to the time after onset of disease in 6 monthly epochs, there was a rise in levels as 
disease progressed, and a fall later in disease.  
 3.3   Relationship to Survival of  pNfH levels and of the Rate of Change of pNfH levels 
To determine whether the levels of pNfH are related to survival from symptom onset, in the 
upper panel of Figure 4A we plot all of the pNfH levels against survival time. This shows an 
inverse relationship between pNfH levels and survival, with linear regression analysis, although 
some subjects with short survival had low pNfH levels. There was also an inverse relationship 
between survival and the first pNfH level (Figure 4B) and the peak pNfH level (Figure 4C).  To 
determine if the rate of rise in pNfH is related to survival, for those subjects with serial samples, 
we also calculated the rate of rise of pNfH, using all available values, and plotted this against 
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survival.  In subjects where there was a decline in pNfH, the rate of rise was taken to be zero. 
This is shown in the lower panel of Figure 4D. There is a significant relationship between the 
rate of rise of pNfH and survival.  
Having shown that the values of pNfH rise with time, and that there is a relationship between 
survival and the peak pNfH level, but not the first pNfH level, we have also plotted the 
relationship of survival and pNfH for samples collected at different times after onset of disease. 
This is shown in Figure 5. For the samples collected 0–12 months after onset, the survival was 
generally less than 1000 days, and there was no correlation with survival. For the samples 
collected at 12–24  months after onset, and those collected at 24–36 months after onset, higher 
values of pNfH were associated with reduced survival. The samples collected after 36 months 
from onset were from subjects with long survival, and  for these samples, there was no 
correlation with survival. These data accord with our serial studies that show that levels of pNfH 
increase in the first part of the disease course,  and that the rate of rise of pNfH may be a better 
predictor of survival.   
 
3.4 Relationship to Clinical Features of ALS Subjects 
We examined the relationship of pNfH levels and  the rate of rise of pNfH  to clinical features of 
the ALS subjects. There was no significant difference between males and females in pNfH levels 
or the rate of rise of pNfH (Supplementary Figure 1).   Table 2 gives the numbers of subjects 
with typical ALS, UMN predominant and LMN predominant phenotypes. There was no 
significant difference among the groups in the levels of pNfH or the rate of rise of pNfH 
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(Supplementary Figure 2). The numbers of subjects with onset in bulbar, upper limbs and lower 
limbs are shown in Table 2. There was no difference in the pNfH levels or the rate of rise of 
pNfH among these groups (Supplementary Figure 3). There was no significant difference 
between the Rilutek treated subjects and untreated subjects in the levels of pNfH. There was a 
reduction in the rate of rise of pNfH in subjects on Rilutek, this was not statistically significant  
(Supplementary Figure 4). In Figure 6A we  show that there was no association between age and 
pNfH levels in healthy controls, but there was was a significant association between the age and 
the peak levels of pNfH protein (Figure 6B). There was  no significant association between age 
and the rate of rise of pNfH protein (Figure 6C). In our subjects there was a significant inverse 
association between age at onset and survival from onset (Supplementary Figure 5). 
 
We examined the relationship of pNfH and rate of change of pNfH to the ALSFRS-R score at 
the time of blood collection and to the rate of change of ALSFRS-R. There was no relationship 
of the pNfH level to the ALSFRS-R at the time of blood collection (data not shown).  As shown 
in Figure 7A, there was an apparent inverse relationship between peak pNfH levels and rate of 
change of ALSFRS-R. For the small number of subjects for whom this data was available, there 
was a greater rate of rise of pNfH in those with a greater rate of decline of ALSFRS-R, but this 
was not statistically significant (Figure 7B).   
4.  Discussion 
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We report the results of a serial study of levels of pNfH in subjects with ALS, using a 
commercially available ELISA kit, with a polyclonal antibody to pNfH. Overall, serum pNfH 
levels were significantly higher in ALS subjects than in control subjects, as has been shown 
previously [14;18]. After CNS injury, pNfH is released into the extracellular fluid from where it 
diffuses into the CSF and finally enters the blood stream via the arachnoid villi. We have 
previously shown that pNfH levels are elevated after stroke [9] and others have found that pNfH 
levels are elevated in multiple sclerosis [30] which indicates that pNfH can enter the blood after 
CNS damage in humans  After degeneration of peripheral axons, we expect that pNfH could 
readily enter the blood stream. Therefore we expect that the pNfH levels in ALS will reflect 
damage of both upper and lower motor neurones. 
In our serial study, we found that, in many subjects, the levels of pNfH increased over time in 
the early stage of disease. It also shows a possible decline in levels in the later part of disease. 
There have been two previous serial studies of pNfH levels in humans. One study followed 
patients monthly for 4 months and found no change in levels of pNfH [18]. This is a short time 
frame compared to our study, and does not show what happens with prolonged observation. The 
only other serial study, which followed patients for three years, also showed that levels changed 
with time, and that for some subjects the levels increased and for others the levels decreased 
[15].  Our study gives similar results. The novel aspect of our study is that we followed patients 
for prolonged periods, and in 68 of the 98 subjects, the folowup was until death. In a study in 
SOD1 mutant mice, it has been shown that pNfH levels increase as disease progresses up to day 
120 [31]. This study did not extend to the end stage of disease (150-180 days) when, as we have 
shown,  few axons remain [32], and we suggest that it is possible that the levels would decline if 
mice were samples at this later stage.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
Our study included some subjects with ALS with prolonged survival, as has been reported in 
14% of ALS subjects [21]. We found that pNfH levels were greater in subjects with shorter 
survival, and that there was an inverse correlation between pNfH levels and survival. It has 
previously reported that high levels early in disease are linked with more rapid progression [15]. 
We calculated the rate of rise of pNfH levels and found that this was inversely correlated with 
survival. These data suggest that high levels and a rapid increase in pNfH levels are related to 
disease severity and are associated with poor prognosis.  We note that some patients with low 
pNfH levels had short survival. This could occur if the levels were underestimated because of the 
development of antibodies to pNfH, as has been described [15;33]. However, another issue is 
that survival is not always related to disease severity, and can be shorter in subjects with early 
respiratory involvement and  longer in subjects treated with non-invasive or invasive ventilation.  
To account for the increase in levels of pNfH as disease progresses, and the possible decline 
in levels at the end of the disease course, we suggest that the level of pNfH in the blood would be 
related to the number of axons being degraded in per unit of time, which would add pNfH to the 
blood. Neurofilaments are susceptible to proteolysis within cells [34;35] and are likely to be 
removed from the circulation by proteolysis, which would clear pNfH from the blood. In human 
ALS, little is known about the kinetics of the loss of motor neurones, but this would be 
dependent on the number of axons remaining and the rate of axonal degeneration.  Possible 
mathematical models of the loss of motor neurones include a linear decay, an exponential decay 
or an accelerating process.  There has been a  theoretical study of this topic  [36] but there is little 
data to indicate which of these models applies to human ALS, although in inherited 
neurodegenerative conditions there is support for the one-hit model [37],which implies 
exponential decline. For the lower motor neurone, we have data suggesting that the loss of axons 
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from a single muscle follows an exponential decay  [38].  However, the disease spreads from the 
region of onset to other regions and as more regions become involved in the initial stage of 
disease, the number of degenerating motor neurons would be expected to increase. Later in the 
disease, when few motor neurons remain, we would argue that fewer cells would die per day, 
and this would be consistent with our data and the data of Lu et al. showing that levels decline 
later in the course of disease [15].   
Another issue is whether the decline in levels in the later stage of disease could be due to 
increased aggregation of Nf in the later stage of disease, which could reduce the number of 
binding sites available for antibody binding. There is evidence of aggregation of neurofilament in 
neurodegerative disease [17]. However, we think this is less likely as an explanation for a decline 
in levels as disease progresses. We suggest that Nf may progressively aggregate within a neurone, 
until that neurone dies, releasing aggregated protein. If all cells die in a similar fashion, then all the Nf 
released from dead neurones would be expected to show similar levels of aggregation. Therefore, higher 
levels should still represent greater numbers of neurones dying in a given time, and lower levels would 
indicate fewer cells dying.    
To categorize our subjects into those with shorter disease duration and those with longer 
disease duration, we used an arbitrary cutoff of 1500 days (4.1 years) because patients with 
typical ALS are usually thought to have a life expectancy of 3-5 years, and those with longer 
disease duration can be considered to have longer than expected survival. In more rapidly 
progressing disease, we would expect higher levels of pNfH, particularly in the early stages of 
disease, as we have shown, with higher initial of pNfH levels in subjects with survival less than 
1500 days than in subjects with survival more than 1500 days.  
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We found no correlation between the levels of pNfH and ALSFRS-R, which is similar to the 
results of others [14].  We found some association between the initial pNfH levels with the rate 
of change of ALSFRS-R, as has previously been shown [18].  There was also a relationship 
between the rate of rise of pNfH and the rate of change of ALSFRS-R, again suggesting that the 
rate of change of pNfH holds promise as a marker of disease progression. 
We found an association of pNfH levels with age, as has been found previously [18]. This does 
not appear to be due to greater background levels in older subjects, since we found no significant 
association between pNfH levels and age in the control subjects. There was no significnat 
association of age with the rate of rise of pNfH, which could be related to the lower number of 
subjects in this group. Older age is known to be associated with worse prognosis of ALS [39], 
and in our cohort this was the case. This is consistent with our finding of increased pNfH levels 
in older subjects and that pNfH levels are associated with survival. We found no association 
between pNfH levels, or the rate of rise of pNfH levels, and  the site of onset, the phenotype of 
subjects or the use of Rilutek. We have previously found that subjects with upper or lower motor 
neurone predominant disease have a longer half life of motor units   [25], but this was not 
reflected in the levels of pNfH, suggesting that pNfH levels are not as sensitive as measurements 
of neuronal half life.  We did not find an effect of Rilutek  on pNfH levels in ALS patients, 
which was in contrast to the previous findings [14].  There was a slight decrease in the rate of 
rise of pNfH in subjects on Rilutek, but this was not statistically significant.   
There are some limitations of our study. One limitation is that we did not use any methods to 
disrupt Nf aggregates that may occur in ALS as part of the pathological process [28].  This could 
lead to an underestimation of the levels of pNfH, if binding sites are blocked in aggregated 
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protein. Indeed, we found that the levels measured in diluted serum were higher than in undiluted 
serum, suggesting that the “hook  effect” was present.  This needs to be addressed in further 
studies, and there needs to be standardization of assay for multi-centre studies  [29]. [40]. 
Another limitation of our study is that we collected blood from the first visit to our ALS clinic 
and this meant that, for some subjects, the first sample was collected late in the course of disease, 
and it would be preferable if all the first samples were collected as soon as possible after 
diagnosis. Other limitations of our study are that we did not collect serial samples for all 
patients.For consistency, we plotted a straight line to obtain the rate of rise of pNfH, and it is 
possible that the relationship between pNfH levels and time is more complex, and this should be 
further explored. 
In summary, we have confirmed that levels of pNfH are elevated in ALS, and that high levels are 
associated with worse survival, and warrants further exploration as a prognostic marker in ALS,. 
We have shown that the rate of rise of pNfH levels is inversely related to survival, and we 
suggest that this is a measurement that could be used in clincal trials of therapies to reduce 
disease progression. In the future more prospective studies are required and it would be helpful 
to the field if methods could be standardized, including the use of measures to overcome protein 
aggregation.  
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Table and Figure legends  
Table 1: Clinical features of subjects 
This table shows the clinical details of the healthy controls and the ALS subjects. The healthy 
controls (HC)  had only one sample of blood collected. The ALS subjects had up to 9 samples 
collected.  
 
Table 2: Subgroups of ALS subjects 
Patients were divided according to whether they had typical ALS with mixed upper and lower 
motor neurone signs, or had ALS with predominant upper or lower motor neurone weakness, and 
according to the site of onset. The number of subjects in each group is shown. The median 
(interquartile range) of the age and the survival of the subjects in these groups are also shown.  
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Figure 1: pNfH levels  
This shows the levels of pNfH in healthy controls (HC), the total ALS group, the ALS subjects 
with survival less than 1500 days and the ALS subjects with survival more than 1500 days. We 
show the results for all the samples that were collected (ALL) and the first samples (1
st
) and the 
peak levels (PEAK), which are the peak levels if more than one sample was collected, and the 
first level if only one sample was collected. Individual results are shown as open circles and the 
median value for each group is shown as a horizontal line. There is significant elevation of pNfH 
levels in subjects with ALS, compared to controls.  (Kruskal Wallis one-way ANOVA corrected 
for multiple comparisons, asterisk indicates p<0.0001) The greatest levels are seen in the 
subjects with survival <1500 days. 
 
Figure 2:  pNfH serial studies  
Panel A shows the pNfH levels for the subjects who had serial samples, according to the time 
after onset that the sample was collected. Individual results are shown as black circles and the 
serial samples for each individual are linked by a line. Many subjects showed an increase in 
levels with time, but later in the disease the levels were low.  In Panels B and C we show all of 
the samples, including those where only one sample was collected and those with serial samples. 
Panel B shows the values for all subejcts with survival less than 1500 days, with a second order 
polynomial curve fitted.  Panel C shows the values for all subjects with survival more than 1500 
days with a second order polynomial curve fitted.  These curves show that on average there is a 
rise and fall of pNfH levels over time, but it must be noted that there is considerable variability 
among subjects. 
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Figure 3:  pNfH levels over time  
Panel A  shows the levels of pNfH in the first, second, third and fourth or later samples. The 
horizontal bars represent the median values. The subjects were divided into those with survival 
less than 1500 days and those with longer survival. The later samples showed higher values than 
the first sample. (Kruskal Wallis one-way ANOVA corrected for multiple comparisons, asterisk 
indicates p<0.05). In Panels B and C we show all of the samples, including those where only one 
sample was collected and those with serial samples. Panels B and C, which show the results from  
subjects with survival less than 1500 days and more than 1500 days, respectively, show the 
samples grouped according to the time after onset of disease that the sample was collected, in 6 
monthly epochs. There was a rise in levels as disease progressed, and a later decline.  
 
 
 
Figure 4: Survival and pNfH levels  
Panel A shows the relationship between pNfH levels and survival time, for all samples, using 
linear regression analysis. There was a significant inverse correlation. Note that a logarithmic 
scale is used for the survival time.  Panel B shows the relationship between the value of pNfH in 
the first sample collected from each subject and the survival. There was a trend to higher values 
of pNfH being associated with reduced survival, but this was not clinically significant. Panel C 
shows the inverse relationship between the peak value of pNfH and survival. This was 
significant.  Panel D shows the relationship of the rate of rise of pNfH and survival. There was a 
significant inverse relationship between the rate of rise of pNfH and survival, using linear 
regression analysis. Note that a logarithmic scale is used for the rate of rise of pNfH. 
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Figure 5  Effect of timing of sample on relationship between pNfH levels and survival. 
In this figure we have grouped all the samples according to the time after onset of symptoms that 
the samples were collected. We then plotted the relationship between the pNfH level and 
survival for each of these groups of samples. For the samples collected 0-12 months after onset 
(Panel A), the survival was generally less than 1000 days, and there was no correlation with 
survival. For the samples collected at 12-24 months after onset (Panel B), and those collected at 
24-36 months after onset (Panel C), higher values of pNfH were associated with reduced 
survival. The samples collected after 36 months from onset were from subjects with long 
survival (Panel D) and for these samples, there was no correlation with survival. These data 
accord with our serial studies that show that levels of pNfH increase as disease progresses, and 
that the rate of rise of pNfH may be a better predictor of survival.   
 
Figure 6:  pNfH levels and age  
Panel A shows that there was no relationship between pNfH levels and age in the control 
subjects. Panel B shows the relationship between age of the subject at the time of sample 
collection and the levels of pNfH. This was significant, using linear regression analysis.  Panel C 
shows that there was no significant  relationship between age and rate of rise of pNfH.    
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Figure 7:  pNfH levels and ALSFRS-R  
Panel A shows the relation between the peak pNfH level and the rate of rise of ALSFRS-R, for 
the subjects who had serial measurements of ALS-FRS-R. There was a significant inverse 
correlation. Panel B shows the relationship between the rate of change of ALSFRS-R and the 
rate of rise of pNfH. There was an apparent inverse correlation, but this was not statistically 
significant. Note that a logarithmic scale is used for the rate of rise of pNfH.  
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
25 
 
 
Table 1: Clinical details 
 
 
Total 
Number 
Mean 
Age 
(range) 
Percent 
female 
Num
ber 
with 
single 
samp
le 
Number 
with two 
samples 
Number 
with 
three 
samples 
Number 
with 
four or 
more 
samples 
Healthy 
Subjects  
 
59 48 
(21-95) 
61 - - - - 
ALS 
Subjects 
98 61  
(32-81) 
44 43 55 34 14 
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Table 2: Subgroups of ALS subjects 
 
    Number of 
subjects 
Median (IQR) age at 
onset (years) 
Median (IQR) 
survival from onset 
until death or 
censoring (years) 
 
Phenotypes 
 
Typical ALS 
 
63 60.86 (15.85) 3.16 (2.18) 
UMN predominant 
 
10 56.29 (24.48) 6.32 (1.99) 
LMN predominant 
 
25 57.57 (14.17) 4.77 (3.14) 
 
Site of Onset 
 
Bulbar 
 
32 62.79 (9.54) 2.81 (1.76) 
Upper limb 
 
32 58.00 (17.05) 4.05 (2.65) 
Lower limb 
 
34 57.11 (12.59) 4.64 (3.51) 
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Fig. 2 
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Fig. 3 
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Fig. 4 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
 
 
Fig. 5 
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Fig. 6 
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Fig. 7 
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Highlights 
 
Levels of phosphorylated neurofilament heavy (pNfH)  were increased in the serum of subjects 
with amytotrophic lateral sclerosis 
Levels of pNfH increased over time in most subjects 
Levels of pNfH and the rate of rise of pNfH were correlated with survival  
 
 
